Insulin Pricing

This docket consolidates claims alleging that major insulin manufacturers and pharmacy benefit managers conspired to artificially inflate the published list price of insulin products, with manufacturers paying substantial rebates to PBMs in exchange for preferential formulary placement and then raising list prices to cover those payments, allegedly rendering the published prices disconnected from legitimate market forces. Centralized in the District of New Jersey in 2023, the docket carries 516 pending actions, one of the larger active populations among the Sales Practices dockets on the JPML's current report, brought by third-party payors, benefit plans, and other institutional purchasers, with claims including wire and mail fraud and RICO violations alongside state consumer-protection theories.

For a funder, this is primarily an institutional purchaser-overcharge docket rather than an individual personal-injury or consumer matter, though the underlying allegations touch a genuinely sympathetic fact pattern given widely reported instances of patients rationing insulin due to cost. Claim value for the institutional plaintiffs, benefit plans and payors, can be modeled against documented insulin spend and rebate structures, a more tractable damages framework than a diffuse consumer class, while the RICO and fraud theories add both upside and litigation-risk complexity relative to a straightforward antitrust overcharge claim.

That profile supports portfolio and inventory finance for benefit plans, payors, or firms representing multiple institutional purchasers with documented insulin-spend records, a genuine capital opportunity given the docket's scale. Criterica Capital's commercial litigation finance line applies well here, with diligence focused on each purchaser's documented spend and rebate exposure during the relevant period. A structure and litigation brief on the current claim population and legal theories is also available.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.